Trust and Governance

Creative Thinking Institute is the AI-native parent company behind Regenemm Healthcare. CTI's governance role is to keep the research lineage, clinical oversight, privacy posture and product transparency connected as Regenemm matures from research-backed innovation into healthcare infrastructure.

This page is a public orientation layer. It summarises CTI's operating posture without publishing sensitive implementation detail, security evidence, clinical safety files, infrastructure topology or customer-specific audit material. Product-specific trust evidence belongs on Regenemm's Trust Center, security, clinical safety, privacy and disclosure surfaces.

Governance Principles

Clinician-led, AI-assisted

CTI supports AI systems that assist clinicians, patients and care teams. AI may draft, organise, summarise or route information, but clinical judgement and approval remain human responsibilities.

Evidence before claims

Public claims should be traceable to research lineage, product evidence, governance records, validation activities or documented operating controls. CTI avoids presenting prototype capability as deployed clinical safety assurance.

Privacy by design

Healthcare data must be handled with proportionate privacy controls, role-based access, careful disclosure boundaries and clear separation between public education material and protected clinical information.

Auditability and provenance

Clinical AI outputs need traceable source context, review history and release state. CTI's governance model treats provenance as part of the product, not as an afterthought.

Public transparency with internal safeguards

CTI publishes enough context for clinicians, partners, patients and reviewers to understand the operating model. Detailed security controls, customer implementation notes, audit attachments and sensitive clinical safety evidence remain internal.

AI protection and visible controls

AI protection means more than model selection. It includes intended-purpose boundaries, human review, patient-facing release gates, consent-aware sharing, PHI-safe telemetry, audit trails, role-scoped access and clear public statements about what AI may and may not do.

What CTI Oversees

How CTI and Regenemm Coordinate

CTI is the parent-company voice for why the system exists, what principles govern it and how the research lineage informs responsible AI. Regenemm is the product-company voice for how the platform works, how trust evidence is presented, and how clinicians, customers and reviewers enter product-specific security and clinical safety workflows.

This separation is intentional. CTI should make the posture visible. Regenemm should hold the operational trust center.

What Remains Internal

CTI does not publish secrets, protected health information, patient records, customer deployment detail, exploit mechanics, infrastructure topology, access-control internals or private audit evidence. Those records belong in controlled assurance, clinical safety, legal, customer and security processes.

Related Public Surfaces

• CTI and Regenemm Healthcare
• Privacy
• Research Writing
• Regenemm Trust Center
• Regenemm Security
• Regenemm Clinical Safety
• Regenemm Responsible Disclosure